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Abstract 
A rapid and simple liquid chromatographic procedure using micellar mobile phases is 
reported for the separation and determination of four quinolones (pipemidic acid, levofloxacin, 
norfloxacin and moxifloxacin) in pharmaceuticals. 
This purpose was achieved without any previous pretreatment step in a C18 column using 
a micellar mobile phase of 0.15 M sodium dodecyl sulphate, 2.5% propanol and 0.5% 
triethylamine at pH 3, with retention times below 12 min. For detection, the diode-array UV-Vis 
set at 276 nm was used. The limits of detection and quantification were between 8-51 and 28-171 
ng/mL, respectively. This method was validated in terms of intra-day and inter-day precision and 
accuracy, and robustness. Calibration curves over the concentration range of 0.1-50 g/mL were 
linear (r2 > 0.9997) and. Good claim percentages (96–106 %) were obtained in the analysis of 
pharmaceutical formulations. The results show that the procedure is suitable for the routine 
analysis of drugs. 
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1. Introduction 
 
 Quinolones and fluoroquinolones are synthetic antibiotics whose action is based on their 
anti-DNA activity. Since nalidixic acid was discovered [1], a number of structure modifications 
to the quinolone nucleus have been performed to increase antimicrobial activity and to enhance 
the pharmacokinetic performance of these drugs. The general structure consists of a 1-sustituted-
1,4-oxopyridine-3-carboxylic moiety combined with either an aromatic or heteroaromatic ring. 
Fluoroquinolones are quinolones with a fluorine atom at position 6 of the quinolone 
naphthyridine or benzoaxazine ring systems, and belong to the second generation of quinolones. 
They are characterised by their greater effectiveness against bacterial activity [2], and are used in 
both human and veterinary medicine. In humans, they are used to treat an extensive range of 
diseases, including urinary, respiratory and gastrointestinal tract infections [3].  
The analysis of quinolones has traditionally been performed using microbiological 
methods. However, this technique is time-consuming and offers poor precision and specificity. 
Other non-routine techniques, such as terbium (III)-sensitised luminescence [4], capillary 
electrophoresis [5- 7] or immunoaffinity chromatography [8], have also been applied.  
Last generation LC-MS-(MS) equipments has also been used [9-11], although this 
equipment is very expensive and only a few laboratories can afford such instrumentation. High-
performance liquid chromatography (HPLC) has become an important tool for the analysis of 
single and various combinations of quinolones in biological fluids, foods, environmental samples 
and pharmaceutical preparations using either UV or fluorescence as the detection method [12-
27].  
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Micellar chromatographic (MLC) methods offer the advantages of the direct injection of 
samples with no pretreatment other than filtration and the low toxicity of the mobile phases 
employed [28]. MLC has proved to be a useful technique in the determination of diverse groups 
of drugs, such as thiazide diuretics [29, 30], furosemide [31] and trazodone [32] in 
pharmaceutical formulations. 
In this work, a simple chromatographic procedure with micellar mobile phases of SDS for 
the simultaneous determination of pipemidic acid, levofloxacin, norfloxacin and moxifloxacin 
(Figure 1) has been developed and applied to control numerous pharmaceuticals in several 
dosage forms, and validated according to the ICH harmonised tripartite guideline [33]. Although 
these compounds are not administered together, the proposed method allowed the determination 
and quantification of the four quinolones in a single chromatographic run without modifications 
being not necessary a chromatographic system for each compound separately, which make the 
proposed method more economic and faster. 
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Figure 1.  Structures, octanol-water partition coefficient (log P) and acid-based constants of the studied quinolones. 
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2.  Experimental 
 
2.1. Reagents and samples 
Pipemidic acid (PIP) and norfloxacin (NOR) were purchased from Sigma (St. Louis, MO, 
USA), moxifloxacin (MOX) from Bayer (Leverkusen, Germany) and levofloxacin (LEV) from 
Fluka (Milan, Italy). Distilled-deionised water was used throughout. Sodium dodecyl sulphate 
(SDS), sodium dihydrogen phosphate and methanol were obtained from Merck (Darmstadt, 
Germany). Propanol was purchased from Scharlab (Barcelona, Spain). Hydrochloric acid and 
triethylamine were acquired from J.T Baker (Deventer, the Netherlands). 
2.2. Instrumentation 
 The pH of the solutions was measured with a Crison GLP 22 (Barcelona), equipped with 
a combined Ag/AgCl/glass electrode. The balance used was a Mettler-Toledo AX105 Delta-
Range (Greifensee, Switzerland). The vortex shaker and sonification unit were acquired from 
Selecta (Barcelona). The chromatographic system was an Agilent Technologies Series 1100 
(Palo Alto, CA, USA) equipped with a quaternary pump, an autosampler and a UV-Visible 
detector. 
 
2.3. Chromatographic conditions 
 A reversed-phase Kromasil C18 column (150 mm×4.6 mm, 5 m particle size) (Scharlab) 
was used. The selected mobile phase was 0.15 M SDS, 2.5% (v/v) propanol and 0.5% 
triethylamine at pH 3. The flow rate and injection volume were 1 mL/min and 20 L, 
respectively. Experiments were carried out at room temperature and detection was performed at 
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276 nm. Chromatographic signals were acquired and processed with an Agilent ChemStation 
(Rev. A.10.01). 
 
2.4. Mobile and standard solutions preparation 
 The micellar mobile phase was prepared using SDS and 0.5% (v/v) of triethylamine,  
which was buffered with sodium dihydrogen phosphate 0.01 M at pH 3 using HCl 0.1 M and, 
lastly, propanol was added to obtain the desired concentration. 
 Stock solutions of 50 g/mL of each compound were prepared. Drugs were dissolved in 
ethanol with the help of an ultrasonic bath and topped up to the mark on the volumetric flask 
with a 0.1 M SDS solution buffered with phosphate at pH 3. For the analysis of the drugs, 
several standard solutions were prepared in the 1-25 g/mL range. Fresh solutions were prepared 
periodically. 
 
2.5. Pharmaceutical sample preparation 
The pharmaceuticals analysed were tablets and coated capsules. The average weight per 
tablet was calculated from ten units. Tablets were ground and reduced to a fine homogeneous 
powder in a mortar. Several portions of this powder were accurately weighed and sonicated in 
the presence of ethanol (5% v/v of the final content) in an ultrasonic bath. Then 0.1 M SDS 
solution at pH 3 was added to favour the extraction of the analyte, and the ultrasonic bath was 
used again. The excipients in the tablets were not soluble in the micellar medium. Therefore, 
sample solutions were filtered before being injected into the chromatograph. However, filtration 
was always performed directly into the autosampler vials through 0.45 m nylon membranes 
(Micron Separations, MA, USA). 
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3. Results and discussion 
 
3.1 Mobile phase selection 
Preliminary studies were carried out to select an efficient method for the analysis of four 
quinolones. Parameters, such as detection wavelength, mobile phase composition, percentages, 
and optimum pH, have been thoroughly studied. 
Several mobile phases were investigated using different alcohols and percentages. 
Propanol yielded better efficiencies but larger retentions than butanol. However, the peaks of the 
compounds could not be resolved with butanol. Thus, propanol was preferred to optimise the 
separation of the four drugs. 
Quinolones have two ionisable functional groups: carboxylic acid and N4 of the 
piperazine ring. The carboxylic group is normally a stronger acid than the ammonium group and 
has a pka1 value ranging from 5.5 to 9.5 in water. The pka values and octanol-water partition 
coefficients (log P) are shown in Figure 1 [34-36]. Among the different pH media tested, pH 3 
was chosen because good retention times were obtained with narrow and well resolved peaks. 
Furthermore, efficiencies deteriorated when the pH of the mobile phase was increased. 
Bonded silica phases are problematic from the point of view of pH stability and residual 
chemical activity of the unprotected silica support, which can induce tailing peaks and variable 
retention times for basic compounds. Using an amine, such as thiethylamine (TEA), is common 
practice to protect the silanol groups of the stationary phase in order to increase peak efficiencies 
for basic compounds with amine groups. The addition of thiethylamine (TEA) enhanced the 
efficiencies of the four quinolones. However, this amine behaved as another modifier and the 
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retention factors of the compounds lowered. For these reasons, the TEA concentration was 
limited to 0.5%. 
 
3.2. Optimization strategy 
 An optimization study for the mixture of PIP, LEV, NOR and MOX was done. An 
adequate control of the concentrations of both the surfactant and modifier can lead to 
chromatograms presenting a good resolution and sufficient elution strength.  
 In order to optimize the mobile phase composition, the retention equation of the four 
quinolones was obtained using a reduced (five) and selected number of mobile phases – four 
located at the corners of a rectangular factor space and the fifth in its centre. The limits of the 
factor space (surfactant and alcohol) were in the 0.05M to 0.15M and 2.5 to 12.5% ranges for the 
concentration of SDS and the volume of propanol, respectively. The errors in the retention 
factors predicted with these equations were below 2% for all the compounds. The retention 
factors (k), efficiencies (N) and asymmetry factors (B/A) of the four compounds were measured 
and processed with the Michrom software [37, 38], which helps to model the compounds 
retention by taking into account the maximum resolution factor and the minimum analysis time. 
The equation used was: 
  
      (1) 
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bulk water and micelles due to the presence of a modifier, as compared to a pure micellar 
solution (without a modifier).  
The global resolution diagram, and the simulated and real chromatograms for the 
optimum mobile phase obtained are depicted in Figure 2. As can be seen in Figure 2a, resolution 
values close to one (maximum value) can be obtained in a narrow region of SDS (0.12-0.15 M) 
and propanol (2.5-3.5 % (v/v)). The best resolution value was obtained for a composition of 0.15 
M SDS – 2.5% propanol – 0.5% TEA- 0.01 M NaH2PO4 at pH 3 with an analysis time below 12 
minutes. Thus this mobile phase was selected as optimum. Figure 2b and 2c show the simulated 
and experimental chromatogram for the mixture of the four quinolones in the optimum mobile 
phase. The agreement between both is excellent. The chromatographic parameters (k, N and B/A) 
obtained were: 6.6, 1900 and 1.1; 5.7, 1500 and 1.1; 9.1, 1700 and 1.0; and 8.1, 1100 and 1.2 for 
PIP, LEV, NOR and MOX, respectively. 
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Figure 2.  (a) Global resolution diagram, (b) simulated and (c) real chromatogram for a mixture of (1) PIP (1.25 
g/mL), (2) LEV (5 g/mL), (3) MOX (10g/mL) and (4) NOR (2.5 g/mL). Mobile phase: 0.15 M SDS - 2.5% 1-
propanol - 0.5% thiethylamine – pH 3, flow rate: 1mL/min, UV detection at 276 nm. 
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4. Validation 
 
The ICH harmonised tripartite guideline [33] was followed to validate the method. 
 
4.1. Linearity 
Under the selected chromatographic conditions, the linear range of the signal response for 
each drug was studied over the concentration range of 0.1–50 g/mL. Seven different 
concentration levels (0.1, 0.5, 1, 5, 15, 25, 50 g/mL) were obtained for each standard solution, 
and were conveniently diluted with 0.1 M SDS solution at pH 3. Each solution was injected into 
the chromatographic system (n=6), and the average value of the peak areas was plotted against 
the concentrations. Curves were adjusted for linear regression with the least mean squares 
method. All the calibration plots in the concentration range studied were linear and with 
correlation coefficients (r2) higher than 0.9997, as shown in Table 1. 
 
Table 1. Linear regression data and the limits of detection and quantification for PIP, LEV, NOR and MOX 
 
Analyte Slope ± SD Intercept ± SD R2 LOD (ng/mL) LOQ (ng/mL) 
Pipemidic Acid  2.67 ± 0.19 -0.27 ± 0.16 0.9998 8 28 
Levofloxacin 0.83 ± 0.03 -0.149 ± 0.021 0.9997 56 171 
Norfloxacin 2.47 ± 0.14 -0.09 ± 0.07 0.9999 33 100 
Moxifloxacin 0.405 ± 0.024 -0.0199 ± 0.016 0.9999 14 43 
 
4.2. Precision and Accuracy 
In order to determine the intra-day precision and accuracy of the method, four known 
concentrations (0.5, 5, 25 and 50 g/mL) of each drug were analysed on the same day (n=6). 
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Inter-day precision and accuracy were also evaluated over five consecutive days by performing 
six successive injections each day of the same concentrations. The results are summarized in 
Table 2. The low variability and high precision of the results obtained in different days are 
evident, which indicate the usefulness of the method. 
Table 2. Inter-day and intra-day precision and accuracy of analytes 
Analyte Concentration added (g/mL) 
Founda 
(mean ± SD) 
(g/mL) 
Accuracy 
(%) 
Intra-day 
C.V. (%) 
Foundb 
(mean ± SD) 
(g/mL) 
Accuracy 
(%) 
Inter-day 
C.V. (%) 
        
Pipemidic 
Acid 0.5 0.505  ± 0.008 1.6 2.1 0.501  ± 0.007 0.3 
3.0 
 5 4.97 ± 0.15 0.6 3.2 5.00 ± 0.08 0.1 5.1 
 25 24.75 ± 0.13 1.0 0.5 24.7 ± 0.3 0.4 3.9 
 50 50.17 ± 0.19 0.3 0.4 50.11 ± 0.18 0.2 5.2 
        
        
Levofloxacin 0.5 0.4888 ± 0.0011 2.2 0.4 0.499 ± 0.010 0.2 2.8 
 5 4.88 ± 0.08 2.3 1.7 5.03 ± 0.09 0.6 4.9 
 25 24.51 ± 0.14 2.0 0.6 25.2 ± 0.4 0.7 6.4 
 50 50.3 ± 0.6 0.6 1.0 50.16 ± 0.13 0.3 6.3 
        
        
Norfloxacin 0.5 0.505 ± 0.006 1.0 0.1 0.498 ± 0.006 0.3 2.4 
 5 4.90 ± 0.17 1.9 3.5 4.99 ± 0.08 0.1 4.7 
 25 25.20 ± 0.06 0.8 0.3 24.9  ± 0.5 0.4 3.9 
 50 49.9 ± 0.3 0.2 0.7 50.05 ± 0.13 0.1 5.4 
        
        
Moxifloxacin 0.5 0.495 ± 0.007 1.0 1.4 0.496 ± 0.007 0.6 4.6 
 5 4.89 ± 0.06 2.1 1.3 4.97 ± 0.03 0.6 4.3 
 25 24.4 ± 0.3 2.3 1.2 24.85 ± 0.14 0.6 4.4 
 50 50.1 ± 0.9 0.2 1.8 50.15 ± 0.14 0.3 4.3 
        
a n = 6, b n = 5 
 
4.3. Limits of detection and quantification 
The limit of detection (LOD) and quantification (LOQ) for PIP, LEV, NOR and MOX (n 
=10) were determined with the 3.3s criterion and 10 criterion, respectively, using a series of 10 
solutions containing a low concentration. The results were based not only on the standard 
deviation of the response, but also on the slope of a specific calibration curve containing the 
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analyte. Both LODs and LOQs are summarised in Table 1 according to the ICH harmonised 
tripartite guideline [33]. The values of the limits obtained were in ng/ml range doing the 
procedure sensitive enough for routine analysis. 
 
4.4. Robustness 
The robustness of the method was evaluated in terms of SDS (M), percentage of 1-
propanol (%) (v/v), pH, percentage of thiethylamine (%) (v/v) and the flow rate of the mobile 
phase by six replicate injections of a standard solution at 5 g/mL. The RSD (%) of the retention 
times calculated from these variations is shown in Table 3 and was lower than 11.0%. Variation 
of the flow rate values (0.9, 1, 1.1 mL/min) had a stronger influence on the retention of the 
studied compounds than other parameters. However, the variations in all the parameters had no 
significant effect on resolution, peak area and peak shape. 
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Table 3. Evaluation of the robustness of the MLC method 
Chromatographic changes Level PIP LEV NOR MOX 
A: Flow rate (mL/min)  tR (min) tR (min) tR (min) tR (min) 
 -0.1 7.7 7.4 11.3 10.23 
 0 7.6 6.7 10.08 9.06 
 +0.1 6.7 6.10 9.18 8.24 
Mean ± SD  7.7  ± 0.7 6.7 ± 0.7 10.2 ± 1.0 9.2 ± 1.0 
RSD (%)  9.7 10.0 10.3 10.9 
B: SDS concentration (M)      
 -0.05 7.7 6.8 10.3 9.23 
 0 7.6 6.7 10.08 9.06 
 +0.05 7.6 6.7 10.06 9.08 
Mean ± SD  7.64± 0.03 6.76 ± 0.08  10.17 ± 0.16  9.13 ±  0.09 
RSD (%)  0.34 1.12 1.6 1.01 
C: Percentage of butanol 
(v/v) 
     
 -0.1 8.3 7.3 11.20 9.9 
 0 7.6 6.7 10.08 9.06 
 +0.1 6.07 6.7 10.0 9.3 
Mean ± SD  7.8 ± 0.4 6.9 ± 0.3 10.4 ± 0.7 9.3 ± 0.5 
RSD (%)  5.21 4.8 6.4 5.7 
D: pH of mobile phase      
 -0.1 7.7 6.7 10.19 9.14 
 0 7.6 6.7 10.08 9.06 
 +0.1 7.7 6.7 10.21 9.11 
Mean ± SD  7.65  ± 0.03  6.734 ± 0.021 10.16 ± 0.07 9.10 ± 0.04 
RSD (%)  0.3 0.3 0.7 0.4 
 
E: Percentage of TEA (v/v)  
 -0.05 7.7 6.7 10.18 9.10 
 0 7.6 6.7 10.08 9.06 
 +0.05 7.6 6.7 10.11 9.02 
Mean ± SD  7.63 ± 0.03 6.721 ± 0.014 10.13 ± 0.05 9.06 ± 0.04 
RSD (%)  0.4 0.2 0.5 0.5 
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4.5. Analysis of pharmaceutical formulations 
The contents of nineteen pharmaceutical formulations, commercially available in Spain, 
were determined. Calibration curves were constructed by measuring the areas of the 
chromatographic peaks of the duplicate injections of the PIP, LEV, NOR and MOX solutions at 
five increasing concentrations in the 1-25 g/mL range. For each drug, six injections were 
performed using 10 g/mL of each compound. Figure 3 illustrates the chromatograms of the 
pharmaceuticals: pipemidic acid (a), levofloxacin (b), norfloxacin (c) and moxifloxacin (d). The 
excipients were eluted with the dead time or did not absorb at the measuring wavelength. 
The labelled composition of the formulations, recoveries and CV (%) values are shown in 
Table 4. The label claim percentage values were in the 96-106% range and the coefficient of 
variation in the range of 0.2-1.8%. As observed, the results obtained are in accordance with the 
labelled values. Moreover, the excipients were eluted with the dead time or did not absorb at the 
measuring wavelength. 
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a 
0.00 4.00 8.00 12.00 16.00 
b 
0.00 4.00 8.00 12.00 16.00 
    
c 
0.00 4.00 8.00 12.00 16.00 
d 
0.00 4.00 8.00 12.00 16.00 
 
 
 
Figure 3.  Chromatogram of (a) pipemidic acid (Nuril, 400mg), (b) levofloxacin (Stada, 500mg), (c) norfloxacin 
(Sadoz, 400mg) and (d) moxifloxacin (Actira, 400mg) pharmaceutical application (10 g/mL). Mobile phase: 0.15 
M SDS - 2.5% 1-propanol - 0.5% thiethylamine - pH3, flow rate: 1mL/min, UV detection at 276 nm. 
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Table 4. Recoveries of pharmaceutical formulations (n=6) 
Pharmaceutical 
(laboratory) Composition (mg) Found (mg) 
 Label claim 
(%) C.V. (%) 
 Per capsule:    
Urisan Pipemidic acid (400), excipients 415 ± 7 103.7 1.7 
 Per capsule:    
Galusan Pipemidic acid (400), excipients 420 ± 8 104.9 1.8 
 Per capsule:    
Nuril Pipemidic acid (400), excipients 421 ± 4 105.3 0.8 
 Per tablet:    
Normon Levofloxacin (500), excipients 500.0 ± 1.7 100.0 0.3 
 Per tablet:    
Stada Levofloxacin (500), excipients 485 ± 3 96.8 0.6 
 Per tablet:    
Tavanic Levofloxacin (500), excipients 483.7 ± 1.0 96.7 0.21 
 Per capsule:    
Amicrobin Norfloxacin (400), excipients 417.64 ± 1.3 104.4 0.3 
 Per tablet:    
Stada Norfloxacin (400), excipients 407.0 ± 1.8 101.7 0.4 
 Per tablet:    
Nalion Norfloxacin (400), excipients 423.7 ± 1.9 105.9 0.4 
 Per tablet:    
Uroctal Norfloxacin (400), excipients 422.18 ± 1.3 105.5 0.3 
 Per tablet:    
Noroxin Norfloxacin (400), excipients 383.85 ± 1.7 96.0 0.4 
 Per tablet:    
Norflok Norfloxacin (400), excipients 420.3 ± 0.7 105.1 0.17 
 Per tablet:    
Normon Norfloxacin (400), excipients 393.5 ± 0.6 98.4 0.6 
 Per tablet:    
Sadoz Norfloxacin (400), excipients 393 ± 4 98.3 1.14 
 Per tablet:    
Bexal Norfloxacin (400), excipients 421.0 ± 1.5 105.3 0.4 
 Per tablet:    
Esclebin Norfloxacin (400), excipients 384.7 ± 1.8 96.2 0.5 
 Per tablet:    
Octegra Moxifloxacin (400), excipients 394.4 ± 1.9 98.6 0.5 
 Per tablet:    
Proflox Moxifloxacin (400), excipients 406.8 ± 1.6 101.7 0.4 
 Per tablet:    
Actira Moxifloxacin (400), excipients 413 ± 6 103.3 1.3 
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5. Conclusions 
 
 The analytical method developed can be used to simultaneously separate and quantify an 
antibiotic mixture consisting of pipemidic acid, levofloxacin, norfloxacin and moxifloxacin. 
Good sensitivity, linearity and robustness were obtained. RSD values were lower than 2% and 
6.4% for intra- and inter-day analyses, respectively. The recoveries in the pharmaceutical 
samples were within a range of 96-106%, and no interferences from excipients were observed. 
The proposed method is fast, precise, accurate, sensitive and efficient, and the tablet 
formulation of the individual antibiotics studied in this research work can be routinely analysed.  
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